Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedMar 25, 2026
DataAggregated Company Financials
Companies56
  • 7D-0.8%
  • 3M-15.3%
  • 1Y27.4%
  • YTD-14.9%

Over the last 7 days, the Pharma industry has remained flat, although notably Knight Therapeutics gained 11%. The past year has been better, since the industry has gained 27% in that time. As for the next few years, earnings are expected to grow by 62% per annum.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 25 Mar 2026CA$13.8bCA$11.3b-CA$1,705,191,437.0611.5x-8.1x1.2x
Fri, 20 Feb 2026CA$14.3bCA$11.3b-CA$1,904,009,808.6914.8x-7.5x1.3x
Sun, 18 Jan 2026CA$16.6bCA$11.3b-CA$1,960,732,761.7416.1x-8.4x1.5x
Tue, 16 Dec 2025CA$19.2bCA$11.2b-CA$1,912,427,830.0615.1x-10x1.7x
Thu, 13 Nov 2025CA$15.6bCA$11.3b-CA$1,861,895,874.7622.1x-8.4x1.4x
Sat, 11 Oct 2025CA$18.5bCA$11.3b-CA$2,040,987,138.2035.1x-9.1x1.6x
Mon, 08 Sep 2025CA$16.4bCA$11.2b-CA$2,031,100,344.4338.1x-8.1x1.5x
Wed, 06 Aug 2025CA$11.8bCA$11.8b-CA$2,547,740,251.3520x-4.6x1x
Fri, 04 Jul 2025CA$10.0bCA$11.6b-CA$2,508,822,655.1616.9x-4x0.9x
Sun, 01 Jun 2025CA$9.7bCA$11.8b-CA$2,510,213,921.3817.5x-3.9x0.8x
Tue, 29 Apr 2025CA$10.5bCA$11.9b-CA$2,505,961,537.0319.9x-4.2x0.9x
Thu, 27 Mar 2025CA$10.3bCA$12.3b-CA$2,566,825,594.0919.2x-4x0.8x
Sat, 22 Feb 2025CA$12.0bCA$12.1b-CA$2,216,825,481.5123.2x-5.4x1x
Mon, 20 Jan 2025CA$12.6bCA$12.2b-CA$2,421,943,229.6529.8x-5.2x1x
Wed, 18 Dec 2024CA$12.4bCA$12.1b-CA$2,595,462,906.9221x-4.8x1x
Fri, 15 Nov 2024CA$15.3bCA$12.0b-CA$2,679,223,636.4915.8x-5.7x1.3x
Sun, 13 Oct 2024CA$18.4bCA$11.8b-CA$2,699,739,851.4518.1x-6.8x1.6x
Tue, 10 Sep 2024CA$18.6bCA$11.6b-CA$2,699,979,541.6520.1x-6.9x1.6x
Thu, 08 Aug 2024CA$18.6bCA$11.7b-CA$2,624,941,394.3419x-7.1x1.6x
Sat, 06 Jul 2024CA$19.2bCA$11.7b-CA$3,213,217,874.0718.5x-6x1.6x
Mon, 03 Jun 2024CA$21.4bCA$11.9b-CA$3,474,448,041.5912.8x-6.2x1.8x
Wed, 01 May 2024CA$28.8bCA$11.9b-CA$3,447,758,532.9711.5x-8.4x2.4x
Fri, 29 Mar 2024CA$25.6bCA$11.9b-CA$3,497,921,239.789.3x-7.3x2.2x
Sun, 25 Feb 2024CA$23.1bCA$12.0b-CA$4,646,844,959.649.6x-5x1.9x
Tue, 23 Jan 2024CA$21.4bCA$12.4b-CA$6,759,218,301.009.8x-3.2x1.7x
Thu, 21 Dec 2023CA$16.7bCA$12.3b-CA$6,739,941,076.008.1x-2.5x1.4x
Sat, 18 Nov 2023CA$17.0bCA$12.5b-CA$6,839,508,791.007.1x-2.5x1.4x
Mon, 16 Oct 2023CA$18.3bCA$12.4b-CA$7,333,171,191.0013.2x-2.5x1.5x
Wed, 13 Sep 2023CA$23.8bCA$13.0b-CA$7,901,455,552.0015.7x-3x1.8x
Fri, 11 Aug 2023CA$14.5bCA$13.4b-CA$7,758,250,983.0012.1x-1.9x1.1x
Sun, 09 Jul 2023CA$16.6bCA$13.2b-CA$9,521,794,298.0012.4x-1.7x1.3x
Tue, 06 Jun 2023CA$14.8bCA$13.3b-CA$10,416,539,163.0010x-1.4x1.1x
Thu, 04 May 2023CA$15.3bCA$13.5b-CA$10,333,038,463.0012.3x-1.5x1.1x
Sat, 01 Apr 2023CA$16.3bCA$13.4b-CA$10,025,035,485.008.7x-1.6x1.2x
Price to Earnings Ratio

-1.6x


Total Market Cap: CA$16.3bTotal Earnings: -CA$10,025,035,485.00Total Revenue: CA$13.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Canadian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 1.4x is higher than the industry's current PS ratio of 1.2x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 5.5% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market-2.66%
Healthcare-4.20%
Pharma-0.81%
Pharma-0.81%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GUD Knight TherapeuticsCA$6.8110.7%
+CA$64.7m		13.3%PS1.5x
NVRS Noveris Health SciencesCA$2.2011.1%
+CA$31.9m		780.0%PE56.4x
TSND TerrAscendCA$0.986.5%
+CA$18.5m		55.6%PS0.8x
CURA Curaleaf HoldingsCA$3.160%
CA$16.7m		146.9%PS1.4x
QNTM Quantum BioPharmaCA$6.52100.6%
+CA$12.5m		-23.3%PB2.1x

Latest News

CURA
CA$3.16
Curaleaf Holdings
7D
0%
1Y
146.9%
NVRS
CA$2.20
Noveris Health Sciences
7D
11.1%
1Y
780.0%
QNTM
CA$6.52
Quantum BioPharma
7D
100.6%
1Y
-23.3%
GUD
CA$6.81
Knight Therapeutics
7D
10.7%
1Y
13.3%

GUD: Higher Earnings Visibility And 2026 Guidance Will Support Bullish Repricing

Analysts have raised their blended price target for Knight Therapeutics to CA$11.00, supported by updated assumptions on discount rate, revenue growth, profit margin and future P/E, as well as a recent CA$0.50 target move from Street research. Analyst Commentary Recent research commentary points to a more constructive tone around Knight Therapeutics, with the CA$0.50 increase in one target contributing to a higher blended price target of CA$11.00.
ACB
CA$4.59
Aurora Cannabis
7D
-5.2%
1Y
-29.1%

ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook

Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.
CPH
CA$16.52
Cipher Pharmaceuticals
7D
-2.0%
1Y
34.1%
TSND
CA$0.98
TerrAscend
7D
6.5%
1Y
55.6%
HITI
CA$3.13
High Tide
7D
-6.8%
1Y
1.0%
VREO
CA$0.54
Vireo Growth
7D
-6.9%
1Y
-16.9%
WEED
CA$1.32
Canopy Growth
7D
-10.8%
1Y
-16.5%
TRUL
CA$8.45
Trulieve Cannabis
7D
-1.3%
1Y
49.6%

TRUL: Schedule III Shift And Higher P E Assumptions Will Drive Future Upside

Analysts have slightly raised their fair value estimate for Trulieve Cannabis to about CA$14.95 from CA$14.69, reflecting updated assumptions around slower revenue growth, tighter profit margins and a much higher future P/E multiple that mirrors recent Street work, where price targets have been adjusted while views on long term earnings power and business mix continue to evolve. Analyst Commentary Street research around information services and data providers has recently highlighted how quickly sentiment can shift when investors question earnings durability, pricing power or the impact of new technology.
OGI
CA$1.87
Organigram Global
7D
-5.6%
1Y
23.8%
LOBE
CA$0.09
Lobe Sciences
7D
28.6%
1Y
260.0%
MVMD
CA$0.055
Mountain Valley MD Holdings
7D
175.0%
1Y
120.0%
XLY
CA$0.14
Auxly Cannabis Group
7D
3.7%
1Y
64.7%
RVV
CA$0.035
Revive Therapeutics
7D
-50.0%
1Y
250.0%